Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB)’s stock price was up 4.4% during trading on Friday . The company traded as high as $0.90 and last traded at $0.71, approximately 19,472 shares were traded during mid-day trading. A decline of 90% from the average daily volume of 196,095 shares. The stock had previously closed at $0.68.
Separately, Maxim Group began coverage on Navidea Biopharmaceuticals in a report on Thursday. They set a “buy” rating and a $2.00 price target on the stock.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter. The company had revenue of $0.14 million during the quarter.
In related news, major shareholder John K. Jr. Scott acquired 4,000,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was bought at an average cost of $0.75 per share, with a total value of $3,000,000.00. Following the completion of the acquisition, the insider now owns 5,113,078 shares in the company, valued at $3,834,808.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have acquired 4,011,300 shares of company stock valued at $3,018,490.
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu Financial LLC grew its holdings in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 186,972 shares of the biopharmaceutical company’s stock after buying an additional 90,647 shares during the quarter. Virtu Financial LLC owned approximately 0.09% of Navidea Biopharmaceuticals worth $26,000 at the end of the most recent reporting period.
Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Featured Story: What is the Coverage Ratio?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.